Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathias Winkler

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
European Urology Oncology|June 14, 2025
Combination Cytoreductive Surgery, Radiotherapy, or Ablation for De Novo Metastatic Prostate Cancer: The IP2-ATLANTA Internal Pilot, Phase 2, Randomised Controlled TrialMartin J Connor, Taimur T Shah, Johanna Sukumar, et al.
Health Technology Assessment (Winchester, England)|July 25, 2018
Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS studyLouise Clare Brown, Hashim U Ahmed, Rita Faria, et al.
European Urology|October 1, 2023
The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST TrialAlexander Light, Abi Kanthabalan, Marjorie Otieno, et al.
European Urology|May 7, 2020
What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS CohortJoseph M Norris, Lina M Carmona Echeverria, Simon R J Bott, et al.
European Urology|April 4, 2022
Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After RadiotherapyTaimur T Shah, Abi Kanthabalan, Marjorie Otieno, et al.
European Urology|February 6, 2022
Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year ExperienceDeepika Reddy, Max Peters, Taimur T Shah, et al.
BJU International|June 29, 2023
External validation of a risk model predicting failure of salvage focal ablation for prostate cancerAlexander Light, Max Peters, Deepika Reddy, et al.
European Urology|January 21, 2023
Corrigendum to "Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial" [Eur Urol 2022;81(6):598-605]Taimur T Shah, Abi Kanthabalan, Marjorie Otieno, et al.
The Lancet. Oncology|March 3, 2022
Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory studyAlistair D R Grey, Rebecca Scott, Bina Shah, et al.
Scientific Reports|October 15, 2020
A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologistsLina Maria Carmona Echeverria, Aiman Haider, Alex Freeman, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
European Urology Oncology|June 14, 2025
Combination Cytoreductive Surgery, Radiotherapy, or Ablation for De Novo Metastatic Prostate Cancer: The IP2-ATLANTA Internal Pilot, Phase 2, Randomised Controlled TrialMartin J Connor, Taimur T Shah, Johanna Sukumar, et al.
Health Technology Assessment (Winchester, England)|July 25, 2018
Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS studyLouise Clare Brown, Hashim U Ahmed, Rita Faria, et al.
European Urology|October 1, 2023
The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST TrialAlexander Light, Abi Kanthabalan, Marjorie Otieno, et al.
European Urology|May 7, 2020
What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS CohortJoseph M Norris, Lina M Carmona Echeverria, Simon R J Bott, et al.
European Urology|April 4, 2022
Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After RadiotherapyTaimur T Shah, Abi Kanthabalan, Marjorie Otieno, et al.
European Urology|February 6, 2022
Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year ExperienceDeepika Reddy, Max Peters, Taimur T Shah, et al.
BJU International|June 29, 2023
External validation of a risk model predicting failure of salvage focal ablation for prostate cancerAlexander Light, Max Peters, Deepika Reddy, et al.
European Urology|January 21, 2023
Corrigendum to "Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial" [Eur Urol 2022;81(6):598-605]Taimur T Shah, Abi Kanthabalan, Marjorie Otieno, et al.
The Lancet. Oncology|March 3, 2022
Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory studyAlistair D R Grey, Rebecca Scott, Bina Shah, et al.
Scientific Reports|October 15, 2020
A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologistsLina Maria Carmona Echeverria, Aiman Haider, Alex Freeman, et al.
Pageof 10